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A B S T R A C T

Background: Naturally occurring variation in Membrane-bound O-acyltransferase domain-containing 7
(MBOAT7), encoding for an enzyme involved in phosphatidylinositol acyl-chain remodelling, has been associated with fatty liver and hepatic disorders. Here, we examined the relationship between hepatic Mboat7
down-regulation and fat accumulation.
Methods: Hepatic MBOAT7 expression was surveyed in 119 obese individuals and in experimental models.
MBOAT7 was acutely silenced by antisense oligonucleotides in C57Bl/6 mice, and by CRISPR/Cas9 in HepG2
hepatocytes.
Findings: In obese individuals, hepatic MBOAT7 mRNA decreased from normal liver to steatohepatitis, independently of diabetes, inﬂammation and MBOAT7 genotype. Hepatic MBOAT7 levels were reduced in murine
models of fatty liver, and by hyper-insulinemia. In wild-type mice, Mboat7 was down-regulated by refeeding
and insulin, concomitantly with insulin signalling activation. Acute hepatic Mboat7 silencing promoted
hepatic steatosis in vivo and enhanced expression of fatty acid transporter Fatp1. MBOAT7 deletion in hepatocytes reduced the incorporation of arachidonic acid into phosphatidylinositol, consistently with decreased
enzymatic activity, determining the accumulation of saturated triglycerides, enhanced lipogenesis and FATP1
expression, while FATP1 deletion rescued the phenotype.
Interpretation: MBOAT7 down-regulation by hyper-insulinemia contributes to hepatic fat accumulation,
impairing phosphatidylinositol remodelling and up-regulating FATP1.

Abbreviations: ALD, alcoholic liver disease; APOB, Apolipoprotein B; BMI, Body Mass Index; CDP, Cytidine-Diphosphate; CI, Conﬁdence Interval; CL, Cardiolipin; CPT1, Carnitine
Palmitoyltransferase I; CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats; CXCL10, C-X-C Motif Chemokine 10; DAG, Diacylglycerol; FABP1, Fatty Acid-Binding Protein 1, FAS, Fatty Acid Synthase; FATP1, Fatty Acid Transport Protein 1; FOXO1, Forkhead Box protein O1; FOXA2, Forkhead Box A2; G3P, Glyceraldehyde-3-Phosphate; HDL, High
Density Lipoproteins; hHEPS, Human Hepatocytes; hHSC, Human Hepatic Stellate Cells; HOMA-IR, homeostasis Model Assessment of Insulin Resistance; IFG, Impaired Fasting Glucose; i.p., Intraperitoneal; i.v., Intravenous; LDL, Low Density Lipoproteins; LPA, Lyso-Phosphatidic Acid; LPIAT1, Lysophosphatidylinositol Acyltransferase 1; Mboat7, Membrane
bound O-acyltransferase domain containing 7; MCD, methionine choline deﬁcient diet; MPO, morpholino; mTOR, mammalian target of Rapamycin; MTTP, Microsomal Triglyceride
Transfer Protein; NAFLD, nonalcoholic fatty liver disease; NASH, Nonalcoholic Steatohepatitis; NHEJ, Non-Homologues End Joining; OA, Oleic Acid; PA, Palmitic Acid; PC, Phosphatidylcholine; ORO, Oil Red O Staining; PE, Phosphatidyl-Ethanolamine; PG, Phosphatidyl-Glycerol; PI, Phosphatidylinositol; PIP, Phosphatidyl-Inositol-Phosphate; PI3K, Phosphatidylinositol 3 Kinase; PNPLA3, Patatin-like Phospholipase Domain-containing-3; PPARa, Peroxisome Proliferator-Activated Receptor alpha; PS, Phosphatidyl-Serine; qRT-PCR,
quantitative Real Time Polymerase Chain Reaction; SD, Standard Diet; SREBP1c, Sterol Regulatory Element-Binding Protein 1; TAG, Triglycerides; TGFb, Transforming Growth Factor
Beta; TM6SF2, Transmembrane 6 Superfamily Member 2; TMC4, Transmembrane Channel-Like 4; TNFa, tumor Necrosis Factor Alpha; T2DM, Type 2 Diabetes Mellitus; VLDL, Very
Low Density Lipoprotein
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Research in context
Evidence before this study
Fatty liver, associated with obesity, type 2 diabetes and at-risk
alcohol intake is the leading cause of liver disease worldwide.
Inherited genetic factors play a major role in the development
of fatty liver. Naturally occurring variation in the MBOAT7 gene,
associated with reduced expression, have been linked to fatty
liver and liver cancer. However, the mechanism linking
MBOAT7 down-regulation with liver disease is still debated.
Added value of this study
We examined relationship between hepatic MBOAT7 downregulation and fat accumulation in clinical samples, experimental models of NAFLD in vivo, and in genetically edited hepatocytes in vitro. We showed that, independently of the genetic
background, down-regulation of Mboat7is a maladaptive
response to hyper-insulinemia and facilitates intracellular fat
accumulation in hepatocytes. The mechanism is related to
impaired generation of arachidonoyl-phosphatidylinositol,
leading to the conversion of saturated lyso-phosphatidylinositol to triglycerides, and enhanced lipogenesis.
Implications of all the available evidence
Down-regulation of MBOAT7 by hyper-insulinemia contributes
to fatty liver independently of the genetic background. The
underlying mechanism encompasses an impairment of intracellular phosphatidylinositol remodelling and lipid ﬂuxes.
These ﬁndings provide novel insight into the pathogenesis of
fatty liver disease.

1. Introduction
Excessive hepatic fat accumulation, triggered by dysmetabolism
and/or at-risk alcohol intake such as in nonalcoholic and alcoholic
fatty liver disease (NAFLD and ALD), is the most frequent cause of
liver disease worldwide, affecting more than one third of the general
population. NAFLD is epidemiologically associated with obesity, metabolic syndrome features and type 2 diabetes (T2D) [1,2]. Fatty liver
encompasses a wide spectrum of liver damage, ranging from isolated
steatosis to nonalcoholic steatohepatitis (NASH), that more frequently evolves to cirrhosis and liver cancer (hepatocellular carcinoma: HCC) [3].
Fatty liver disease development is heavily inﬂuenced by inherited
factors [4,5]. The main common genetic determinants of fatty liver
are the variants in PNPLA3 (p.I148M) [6], and TM6SF2 (p.E167K) [7]
genes. A genome-wide screening of the inherited genetic variants
associated with alcoholic cirrhosis led to the identiﬁcation of the
common rs641738 C>T single nucleotide polymorphism at the Membrane bound O-acyltransferase domain-containing 7 Transmembrane
channel-like 4 (MBOAT7-TMC4) locus [8 10]. We showed that the

minor rs641738 T allele is associated with increased predisposition
towards hepatic fat accumulation and to the entire spectrum of liver
damage related to NAFLD, including HCC [11 13]. Furthermore, the
rs641738 variant has been associated with increased risk of liver
ﬁbrosis in patients with chronic viral hepatitis [14,15], suggesting
that MBOAT7 variation is a common modiﬁer of liver disease risk.
MBOAT7, also known as lyso-phosphatidylinositol (lyso-PI) acyltransferase 1 (LPIAT1), is involved in phospholipid acyl-chain remodelling of the membranes within the Lands’ cycle. It conjugates an
acyl-CoA to the second acyl-chain of lyso-PI and other lyso-phospholipids, using as preferential substrate arachidonoyl-CoA. This process
increases the desaturation of phospholipids using free arachidonic
acid, a precursor of the proinﬂammatory eicosanoids [16 21]. We
previously reported that the likely mechanism behind the genetic
association with liver damage is related to reduced hepatic expression of the MBOAT7 protein in carriers of 30 -untranslated region variants linked with rs641738 [11,13], leading to reduced hepatic PI
species bound to polyunsaturated fatty acids [11,12].
Here we shown that, independently of the genetic background,
down-regulation of hepatic MBOAT7 is a maladaptive response to
hyper-insulinemia that induces fat accumulation in hepatocytes. We
tested this hypothesis in clinical samples of patients, in experimental
models of NAFLD and in response to normal physiological cues
in vivo, and by genetic manipulation of hepatocytes in vitro.
2. Materials and methods
2.1. Patients
We evaluated hepatic and adipose tissue samples of 119 unselected severely obese individuals, who underwent percutaneous liver
biopsy performed during bariatric surgery, and had no history of atrisk alcohol intake (>30/20 g/day in males/females) or other liver diseases (Bariatric surgery cohort). NASH was diagnosed when steatosis,
lobular inﬂammation and ballooning were concomitantly present.
Informed written consent was obtained from each patient and the
study protocol was approved by the Ethical Committee of the Fondazione IRCCS Ca’ Granda and conforms to the ethical guidelines of the
1975 Declaration of Helsinki. The clinical characteristics of these
patients are listed in Table S1.
Serum free fatty acids (FFAs) were measured in 72 NAFLD
patients, of whom samples were available (Hepatology service
cohort). Clinical characteristics are listed in Table S2.
Human hepatocytes and hepatic stellate cells (hHSC) were isolated from non-neoplastic tissue obtained from explanted or resected
livers of 17 patients, while peripheral blood lymphocytes and monocytes were isolated from 16 healthy subjects. The detailed isolation
protocols, and enrolment criteria are described in the Supplementary
Methods.
All patients were genotyped for PNPLA3 rs738409 (p.I148M) and
MBOAT7 rs641738 by TaqMan 50 -nuclease assays (Life Technologies,
Carlsbad, CA) [11,22].
2.2. Experimental models
C57Bl/6 mice (Charles River, Calco, Italy) were housed at constant
room temperature (23 °C) under 12-hour light/dark cycles with ad
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libitum access to water in compliance with the Principles of Laboratory Animal Care (NIH publication 86 23). C57Bl/6 Lepob/ob mice
were purchased from Charles Rivers (Calco, Italy). Insulin receptor
haplo-insufﬁcient (InsR+/-) mice on C57Bl/6 background were kindly
provided by Prof. Accili, Columbia University, NY, USA [23].
Wild-type and InsR+/- male mice, which are more susceptible to
develop liver damage and ﬁbrosis compared to females, were fed
either methionine choline deﬁcient diet (MCD: 14.8% protein, 12.4%
fat and 72.8% carbohydrates; Test Diet, London, UK) or regular chow
(standard diet: SD): 15.1% protein, 12.4% fat and 72.4% carbohydrates
Test Diet, London, UK) for 6 weeks, starting at 6 weeks of age. Experiments were conducted in 10 mice per group. Before sacriﬁce, mice
were fasted for 16 h and the interventions were done during the light
cycle. Metabolic and biochemical features of InsR+/+ and InsR +/mice upon SD or MCD feeding and Lepob/ob mice upon standard diet
are shown in Table S3. In order to evaluate the physiological regulation of Mboat7 in response to the nutritional state, 6 weeks old wildtype male mice were fasted for 16 h (T0), refed, giving them ad libitum access to SD and then sacriﬁced at the following time points
(before refeeding (T0), 15 min (T15’), 1hr (T1h), 4 hrs (T4h), 8 hrs
(T8h)). In another experimental setting, wild-type male mice fasted
for 16 h, injected with i.p. insulin (0.6 U/Kg) and then sacriﬁced at the
following time points (before insulin (T0), 1hr (T1h) and 4 hrs (T4h)).
These experiments were conducted in 7 mice per group per each
time point.
The experimental protocol was approved by the University of
Milan and the Italian Ministry of Health Review Boards (protocols 8/
14 and 295/2012 A, received on 12/20/2012).
2.3. Gene silencing
To silence Forkhead box protein O1 (FoxO1) and/or Forkhead Box A2
(FoxA2), key mediators of insulin signalling at transcriptional level
[24 27], we exploited speciﬁc antisense oligonucleotides conjugated
with morpholinos (MPO) that block protein translation or the “Standard control”. The respective sequences were: 50 -CCACCAGCAGAGAAGTACCGGGAGA-30 , 50 -TCCATCTTCACGGCTCCCAGCATAC-30 and
50 -CCTCTTACCTCAGTTACAATTTATA-30 (Gene tools, www.gene-tools.
com). Primary mouse hepatocytes were isolated as previously
described [28] and incubated with FoxO1 and/or FoxA2-speciﬁc or
scramble MPO (10 mM) for 24 h then exposed to 0.33 mM insulin
(Insuman Rapid, Sanoﬁ Aventis) for 6 h.
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In order to acutely silence in vivo Mboat7, wild-type male mice
were treated with 12.5 mg/kg of Mboat7-speciﬁc MPO (50 -ATATGTCCATTCTTCGGGTGTCAT-30 ) or scramble administered i.v. daily for
4 days (n = 6 per group). These mice were fed SD and fasted for 16 h
before the sacriﬁce. Metabolic and biochemical features of mice
treated with Scramble and anti-Mboat7-MPO are shown in Table S4.
2.4. Lipidomics
For lipidomic analysis, 106 hepatocytes were homogenized with
300 ml of methanol and 20 ml of a mix of internal standards (Avanti
Polar Lipids, Alabaster, AL and Larodan, Solna, SE) were added to samples, which were then put on an oscillating plate for 30 min at 4 °C
and centrifuged at 14,000 rpm. Afterwards, the methanol supernatant was analysed by liquid chromatography / mass spectrometry
quadrupole time of ﬂight (LC/MS-QTOF; Agilent UHPLC 1290 Inﬁnity6540 QTOF, Santa Clara, CA). Separation of lipids obtained from mice
livers is described in the Supplementary Methods.
Lipid classes were separated with ultra-high pressure liquid chromatography (UHPLC) equipped with ZORBAX Eclipse Plus C18
2.1 £ 100 mm 1.8 mm columns (Agilent, Santa Clara CA), and lipids
concentrations measured by MS-QTOF in both positive (for ceramides, sphyngomyelins, phosphatidyl-ethanolamines, phosphatidylcholines (PC), Lyso-PCs, diacylglycerols (DAG), triglycerides (TAG))
and negative electrospray ionization (for PI). To measure the contribution of de novo lipogenesis to intracellular fat accumulation, 10%
deuterium (D2O) was added to the culture media (DMEM supplemented with 10% FBS, 1% L-Glu, 1% P/S) for 24 h [29]. The contribution
of de novo lipogenesis of DAG/TAG synthesis was calculated by D2O
enrichment divided by the number of hydrogens that can exchange
D2O with the water pool and by%D2O added to the medium (10%)
[29]. The detailed protocol is shown in the Supplementary Methods.
2.5. MBOAT7 deletion in HepG2 hepatocytes
MBOAT7 / knockout clones were generated by exploiting the
CRISPR-Cas9 technology following non-homologues end joining
(NHEJ) in HepG2 hepatoma cells (ATCC HB-8065), which are homozygous for the PNPLA3 I148M variant. Mboat7 variation has additive
effect with the I148M PNPLA3 variant on the risk of NAFLD [11 13],
making HepG2 an ideal model to test the impact of Mboat7 downregulation on lipid metabolism. The detailed protocol of CRISPR-Cas9

Fig. 1. Hepatic MBOAT7 expression decreases with liver damage severity and MBOAT7 rs641738 C>T affects MBOAT7 expression in human hepatocytes.
Hepatic MBOAT7 mRNA levels were evaluated by qRT-PCR in 119 severely obese patients stratiﬁed by liver damage severity (A). Demographic, anthropometric and clinical characteristics of these patients are shown in Table S1. Boxes span from 25° to 75° percentile, while whiskers indicate the 10° and 90° percentile. Data is normalized to b-actin, logtransformed and expressed as fold increase (Arbitrary Units - AU). * adjusted p<0.05. MBOAT7 mRNA levels were evaluated by qRT-PCR in freshly isolated human hepatocytes
(hHEPS) and activated human hepatic stellate cells (hHSCs, at third passage) stratiﬁed by the presence of MBOAT7 rs641738 T allele. The mRNA levels were normalized for b-actin
and expressed as fold increase (Arbitrary Units - AU), as compared to CC genotype. (n = 17 hHEPs; n = 12 hHSCs) *p<0.05 compared to hHEPs or hHSCs carrying the protective CC
genotype by two-tailed Student’s t-tests (B).
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Fig. 2. Hepatic Mboat7 expression is down-regulated in experimental models of NAFLD/NASH and hyper-insulinemia.
Hematoxylin and Eosin (H&E) stain of hepatic specimens (A) and hepatic triglyceride (TG) content (B) from wild-type mice fed standard diet (referred to as Cnt) or Methionine
choline deﬁcient diet (MCD) and from Lepob/ob mice. Original magniﬁcation: 200X. Serum insulin was measured in mice fasted for 16 h (n = 10 per group) (C). Hepatic Mboat7
mRNA levels were evaluated by qRT-PCR, and mRNA levels were normalized for b-actin and are expressed as fold increase (Arbitrary Units - AU), as compared to Cnt (D). Western
blot and quantiﬁcation of Mboat7 protein levels in livers from Cnt, MCD and Lepob/ob mice, fasted 16 h (n = 10 per group) (E). * adjusted p<0.05, ** adjusted p<0.01 compared to Cnt.
H&E stain of hepatic specimens from wild-type and InsR+/- mice fed standard diet (SD) or MCD (F). Original magniﬁcation: 200X. Hepatic Mboat7 mRNA levels were evaluated by
qRT-PCR. mRNA levels were normalized for b-actin and expressed as fold increase (Arbitrary Units - AU), as compared to wild-type SD (InsR+/+ SD) (G). Western blot and quantiﬁcation of Mboat7 protein levels in livers pooled from wild-type and InsR+/- MCD mice, fasted for 16 h (n = 10 per group) (H). * adjusted p<0.05; ** adjusted p<0.01 compared to InsR+/+
SD. All reactions were performed in duplicate in the same gel.
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pipeline, the characterization of MBOAT7 / cells carrying different
deletions (D31, D101 and D917) in homozygosis, and their sequences are summarized in the Supplementary Methods and in Fig. S1. In
another experimental setting, we managed to achieve restoration of
basal levels of FATP1 expression generating a double stable model of
MBOAT7 / /FATP1+/- hepatocytes (Fig. S2).
To induce lipid accumulation, visualized by Oil Red O (ORO) staining [30], cells were exposed for 24 h to a combination of palmitic
(PA) and oleic (OA) acids (ratio 1:2), at the ﬁnal concentration of
125 mM (Sigma-Aldrich, St Louis, MO). ORO positive areas were
quantiﬁed by ImageJ software in 10 random micrographs (magniﬁcation 200x). To mimick hyper-insulinemia and insulin resistance and
study the activation of mTOR signalling, cells were incubated with
0.33 mM insulin (Sanoﬁ Aventis) alone or in combination with
0.33 mM glucose (Sigma-Aldrich, St Louis, MO) for 6 h, in DMEM supplemented with 0.5% BSA, 1% L-Glu, 1% P/S.
2.6. Statistics
For descriptive statistics, continuous variables were reported as
mean and standard deviation or median and interquartile range for
highly skewed biological variables. Variables with skewed distributions were logarithmically transformed before analyses. Differences
between groups were calculated by two-tailed ANOVA; which was followed by post hoc t-tests adjusted for the number of comparisons
when multiple groups were involved (Bonferroni correction). For lipidomic analyses, p values were adjusted by the Dunn's multiple comparisons test. Independent determinants of MBOAT7 and FATP1 mRNA
levels, and of circulating fatty acids, were assessed by multivariate generalized linear model analysis. P values <0.05 (two-tailed) were considered statistically signiﬁcant. Statistical analyses were performed
using JMP 14.0 (SAS, Cary, NC) and Prism software (version 6, GraphPad Software). Software packages for the prediction analysis of Mboat7
promoter are listed in the Supplementary Methods section.
3. Results
3.1. Hepatic MBOAT7 down-regulation is associated with
steatohepatitis and insulin resistance in obese individuals
In severely obese individuals, hepatic MBOAT7 mRNA levels progressively decreased from normal liver to isolated steatosis and steatohepatitis (NASH); (p = 0.01 at ANOVA; adjusted p value=0.012 for
NASH vs. normal liver; Fig. 1A). At multivariate analysis, impaired
fasting glucose/T2D (IFG/T2D; p = 0.04), lobular inﬂammation
(p = 0.005), and the rs641738 T allele (p = 0.001) were independently
associated with reduced MBOAT7 (Table S5; Fig. S3A-B). In the visceral adipose tissue, MBOAT7 expression was 9-fold lower than in
the liver, but IFG/T2D (p = 0.01) and the rs641738 T allele were similarly independently associated with reduced expression (p = 0.02;
Table S5). These data suggest that down-regulation of hepatic
MBOAT7 is associated with hepatic inﬂammation and insulin resistance independently of MBOAT7 genotype.
We then surveyed the expression and regulation of MBOAT7 in different cell types. MBOAT7mRNA levels were similar between hepatocytes and HSCs. However, the rs641738 variant was associated with
reduced MBOAT7 expression only in hepatocytes (p<0.05 for T+ vs. CC
genotype; Fig. 1B). Additional data on MBOAT7 expression in inﬂammatory cells are reported in the Supplementary results and Fig. S3C.
3.2. Hepatic Mboat7 expression is down-regulated in experimental
models of NAFLD
We next evaluated hepatic Mboat7 expression in two complementary mouse models of NAFLD, that is MCD, which induces NASH,
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but not insulin resistance, and genetically obese Lepob/ob mice, which
develop severe insulin resistance without ﬁbrosing NASH. The metabolic and biochemical features of wild-type mice on SD or MCD feeding and Lepob/ob mice are shown in Table S3. As expected, hepatic
TAG content was higher in mice fed MCD compared to standard diet
(p = 0.005 at ANOVA; adjusted p<0.05; Fig. 2A-B), but more so in
Lepob/ob mice (adjusted p<0.01 vs. wild-type mice on SD; Fig. 2A-B).
Fasting insulin, glucose and insulin resistance after insulin tolerance
test were increased in Lepob/ob mice compared to wild-type mice fed
standard diet or MCD (all p<0.05 at ANOVA; all adjusted p<0.05;
Fig. 2C and Fig. S4A-B). In Lepob/ob mice, hyper-insulinemia was paralleled by lower hepatic protein levels of FoxA2, a key regulator of lipid
metabolism, that is transcriptionally active in the fasted state
(p = 0.0002 at ANOVA; adjusted p<0.01 vs. wild-type mice on SD; Fig.
S4C). Hepatic Mboat7 mRNA and protein levels were reduced in
MCD-fed mice (p<0.0001 and p = 0.0016, respectively at ANOVA;
adjusted p<0.05 vs. SD; Fig. 2D-E), but more so in Lepob/ob mice
(adjusted p<0.01 vs. SD; Fig. 2D-E). These data suggest that inﬂammation and hyper-insulinemia are independently associated with
hepatic Mboat7 down-regulation.
3.3. Hepatic Mboat7 down-regulation is linked to hyper-insulinemia
To evaluate the independent contribution of the metabolic state to
Mboat7 regulation, we next examined a genetic model of insulin
resistance. Haplo-insufﬁciency for Insulin receptor (InsR+/-) causes
insulin resistance and hyper-insulinemia, characterized by tonic activation of the Akt signalling pathway in the liver. Metabolic and biochemical features of InsR+/+ and +/- mice on SD or MCD feeding are
shown in Table S3. InsR+/- mice developed more severe steatosis
compared to wild-type mice when fed MCD, whereas no macroscopic
steatosis was detected on SD (Fig. 2F) [28]. Mboat7 mRNA levels were
reduced in InsR+/- compared to wild-type mice, independently of the
diet (adjusted p<0.05; Fig. 2G). However, Mboat7 protein levels were
not signiﬁcantly decreased in InsR+/- compared to wild-type mice fed
a standard diet (p = 0.1; Fig. 2H), whereas they were down-regulated
in both wild-type and InsR+/- mice fed MCD (p = 0.0011 at ANOVA;
adjusted p <0.01 vs wild-type fed SD; Fig. 2H), suggesting that
Mboat7 protein stability is modulated by steatosis/inﬂammation.
3.4. Hepatic Mboat7 down-regulation depends on the nutritional state
and insulin levels
We next examined whether hepatic Mboat7 is physiologically
regulated by excursions in insulin levels following fasting-refeeding
cycles. Following refeeding, there was the expected rise of insulin
levels (p <0.05 vs. T0; Fig. 3A) paralleled by activation of hepatic insulin signalling, as detected by an increased phospho (Ser473)-Akt/Akt
ratio, (p<0.05 vs. T0; Fig. 3A) and by decreased protein levels of
FoxO1/FoxA2 (p<0.05 vs. T0; Fig. 3A). This process was closely followed by down-regulation of both mRNA and protein levels of
hepatic Mboat7 (p<0.05 vs. T0; Fig. 3B). After refeeding, Mboat7
mRNA levels were also down-regulated in the proximal intestine and
the adipose tissue (p<0.05 vs. T0; Fig. S5A-B).
Hepatic Mboat7 mRNA and protein down-regulation can be
reproduced by insulin injection (0.6 U/Kg, by i.p. bolus) independently of feeding (p <0.05 vs. T0; Fig. 3C,D). Insulin downregulated
Mboat7 also in the proximal intestine and in adipose tissue
(p<0.05 vs. T0; Fig. S5C-D).
We next compared the regulation of Mboat7 to Mboat5, the closest paralogue that also catalyzes the incorporation of arachidonic
acid into phospholipids, and has been involved in lipoprotein secretion [31 33]. Differently from Mboat7, Mboat5 was up-regulated
during hyper-insulinemia, suggesting that Mboat7, but not Mboat5,
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Fig. 3. Hepatic Mboat7 expression is modulated by nutritional state and insulin.
Serum insulin (ng/mL) and Western blot and quantiﬁcation of hepatic pSer473-Akt/Akt ratio, FoxO1, nuclear FoxA2 (A) and Mboat7 (B) protein levels evaluated in wild-type
mice, fasted for 16 h (T0) or refed for 15 min (T15’), 1 h (T1h), 4 h (T4h) or 8 h (T8h) (n = 7 per group). FoxA2 nuclear fraction was normalized for Histone-H3 protein levels. Mboat7
mRNA levels were evaluated by qRT-PCR, normalized for b-actin and expressed as fold increase (Arbitrary Units - AU), as compared to T0. *p < 0.05, **p < 0.01 compared to T0.
Western blot and quantiﬁcation of hepatic pSer473-Akt/Akt ratio, FoxO1, FoxA2 (C) and Mboat7 (D) protein levels and serum insulin evaluated in wild-type mice, fasted for 16 h
(T0) or 1 h (T1) and 4 h (T4) after insulin administration (0.6 U/Kg i.p, n = 7 per group). *p < 0.05; **p < 0.01 compared to T0.
Western blot and quantiﬁcation of pSer473-Akt/Akt ratio (E) and Mboat7 protein levels (F) in hepatocytes isolated from wild-type mice (n = 3) and treated with insulin
(0.33 mM), LY294002 (50 mM) or a combination of both for 6 h; * adjusted p < 0.05, ** adjusted p < 0.01 compared to wild-type untreated cells. At least three independent experiments were conducted. For each condition, freshly protein lysates were pooled. All reactions were performed in duplicate in the same gel.
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down-regulation may be involved in hepatic fat accumulation in metabolic disorders (Supplementary Results and Fig. S6A D).
3.5. Mboat7 is down-regulated by insulin signalling in primary mouse
hepatocytes
To test whether Mboat7 down-regulation is a cell autonomous
process dependant on activation of insulin signalling, we isolated
primary hepatocytes from wild-type male mice and exposed them
to insulin (0.33 mM) alone or in combination with a selective PI3K
inhibitor LY294002 (50 mM). Insulin induced a 50% reduction in
Mboat7 protein levels (p = 0.0009 at ANOVA; adjusted p <0.01 vs.
untreated hepatocytes; Fig. 3E,F), which was completely abolished
by LY294002 (adjusted p <0.01 vs. insulin-treated hepatocytes;
Fig. 3E-F). Conversely, mammalian target of Rapamycin (mTOR)
pharmacological inhibition did not restore Mboat7 expression (Fig.
S7A). These data suggest that insulin down-regulates Mboat7 in
hepatocytes in a PI3Kinase-depedent manner. Consistently, in InsR
+/- hepatocytes insulin-dependant down-regulation of Mboat7 was
lost (p<0.01 vs. untreated hepatocytes; Fig. S7B).
Analysis of the human Mboat7 human MBOAT7 promoter predicted the presence of FOXO1/FOXA2 binding sites, close to the
transcription start site of the main MBOAT7 isoform. These binding sites are evolutionary conserved, but not in mice (Fig. S8A-B).
Additional data on Mboat7 regulation by FoxO1/FoxA2 in murine
hepatocytes, showing that these transcription factors are nonetheless required for insulin mediated down-regulation of Mboat7,
are reported in the Supplementary Results and in Fig. S8C-F.
3.6. Acute hepatic Mboat7 down-regulation induces steatosis in mice
To ascertain the causal role of Mboat7 down-regulation on the
development of fatty liver, we silenced Mboat7 in wild-type male
mice by i.v. administration for 4 consecutive days of anti-Mboat7MPO. The metabolic and biochemical features of mice are shown
in Table S4. Anti-Mboat7-MPO induced a 45% silencing of hepatic
Mboat7 (p <0.05 vs. scramble-MPO; Fig. 4A), which is comparable
to that observed in individuals carrying the rs641738 risk variant.
Acute down-regulation of Mboat7 led to an 80% increase in hepatic
TAG content (p <0.05 vs. scramble-MPO; Fig. 4B), and to microvesicular steatosis development. This was associated with an alteration of the lipid species, consistent with decreased enzymatic
activity (Supp. Results and Supp. File). Increased hepatic TAG concentration following Mboat7 down-regulation was not accompanied by detectable changes in circulating glucose, insulin, lipid
levels, and ALT (Table S4).
Steatosis development in mice silenced for Mboat7 was not associated with up-regulation of genes involved in lipogenesis. Indeed,
despite enhanced hepatic phospho-mTOR and Raptor protein levels
(p<0.01 vs. Scr-MPO; Fig. S9A), there was reduced phosphorylation
of the downstream targets p70 s6 kinase and 4E-bp1 (p<0.01 vs.
scramble-MPO; Fig. S9A), consistent with down-regulation of hepatic
Srepb1c and Fasn mRNA levels (p<0.01 vs. scramble-MPO; Fig. 4C).
On the other hand, the expression of genes regulating b-oxidation
(Ppar-a and Cpt1) and VLDL export (Mttp and ApoB) was not affected
(Fig. 4D; Fig. S10A). However, mRNA expression of fatty acids transporters (Fatp1 and Fabp1) was up-regulated in mice exposed to antiMboat7-MPO (p<0.01 and p<0.05 vs. scramble-MPO respectively;
Fig. 4E). Mboat7silencing was not associated with alterations in the
hepatic expression of inﬂammatory cytokines and chemokines
(Fig. 4F). Furthermore, there was no modiﬁcation in the expression of
genes related to Mboat7 (Tmc4 at the same locus and Mboat5; Fig.
S10B). This data supports the notion that reduced Mboat7 expression
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is responsible for fatty liver development in carriers of the rs641738
risk allele.
As Mboat7 was also expressed and downregulated in the adipose
tissue, the impact of the decreased Mboat7 expression on circulating
FFAs in vivo Mboat7 silencing and in patients carrying the rs641738
T allele is reported in the supplementary results, and Tables S4 and
S6. In these experimental conditions and in selected patients, we
could not rule out an impact of Mboat7 down-regulation in promoting adipose tissue lipolysis, which may contribute to hepatic fat
accumulation.
3.7. MBOAT7 deletion increases intracellular fat in hepatocytes
We characterized three independent HepG2 clones carrying
homozygous MBOAT7 gene deletions (D31, D101 and D917; Fig. 5AB and Fig. S1). Strikingly, they all displayed a spontaneous increase in
intracellular fat content (p<0.0001 at ANOVA; adjusted p<0.01 vs.
wild-type untreated; Fig. 5B), with the largest deletions being associated with reduced Mboat7 mRNA abundance (p<0.0001 at ANOVA;
adjusted p<0.01 vs. wild-type untreated; Fig. 5B). In this model, intracellular fat accumulation was associated with induction of the lipogenic program, as detected by up-regulation of SREBP1c and FASn
(p<0.0001 at ANOVA; adjusted p<0.05 vs. wild-type; Fig. 5B), and by
activation of the mTOR pathway (Supp. results and Fig. S9B). In particular, MBOAT7 mRNA and protein levels were almost completely
undetectable in the D917 clone, characterized by the most marked
fat accumulation (p<0.01 vs. wild-type untreated; Fig. 5C). We therefore selected the D917 clone (henceforth MBOAT7 / ) for further
experiments. Notably, MBOAT7 / cells were also more susceptible to
accumulate intracellular lipid droplets after exposure to a combination of fatty acids (PA+OA at a ﬁnal concentration 125 mM; adjusted
p<0.01 vs. wild-type exposed to PAOA 125 mM; Fig. 5D,E). These
results suggest that genetically determined decrease in MBOAT7
expression/activity facilitates hepatocellular fat accumulation in a
cell autonomous manner.
3.8. Impact of MBOAT7 deletion on intracellular lipid species in
hepatocytes
We next examined the impact of MBOAT7 deletion on lipid species composition. MBOAT7 / cells displayed a Lyso-PI/PI composition pattern suggestive of an impairment of MBOAT7 enzymatic
activity (Fig. 6A, Fig. S11A-B and Supp. File). In particular, MBOAT7
deletion was associated with a pattern consistent with reduced concentration of Lyso-PI and PI conjugated with arachidonoyl-CoA
(such as Lyso-PI 20:4, 36:4; 38:3; 38:5; 38:4) and increased PI
(40:5) (adjusted p <0.05, Fig. 6A and Fig. S11A-B), but with a higher
concentration of palmitoyl/oleyl-(Lyso) PI/(total) PI (i.e. Lyso-PI 16:0/
18:0 and PI 36:2/34:1/34:2/32:1 Fig. 6A and Fig. S11A,B). In
MBOAT7 / cells there was also a reduced concentration of unsaturated phosphatidyl-ethanolamine (adjusted p<0.05 vs wild-type;
Fig. 6A, Fig. S11C, and Supp. File).
Besides the higher total DAG and TAG content, MBOAT7 / cells
displayed also a shift in their composition, with a higher concentration of saturated and mono-unsaturated TAG (i.e. TAG 50:0/50:1;
adjusted p <0.05 vs. Wt; Fig. 6A, Fig. S11D and Supp. File). Similarly,
in MBOAT7 / cells we observed lower levels of unsaturated phosphatidyl-choline adjusted p<0.05 vs wild-type; Fig. 6A, Fig. S11E, and
Supp. File).
To examine the relative contribution of de novo lipogenesis to
the accumulation of TAG in MBOAT7 / cells, 10% D2O was added to
the culture media of wt and MBOAT7 / cells. D2O incorporation in
DAG and TAG species was higher in MBOAT7 / cells compared to
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Fig. 4. In vivo silencing of hepatic Mboat7 induces TAG accumulation in hepatocellular lipid droplets Wild-type mice were treated with anti-Mboat7-MPO (12.5 mg/kg) or scrambleMPO (Scr) administered i.v. daily for 4 days (n = 6 per group) and fasted for 16 h before sacriﬁce. Western blot quantiﬁcation of Mboat7 hepatic protein levels were normalized for
b-actin; *p<0.05 compared to Scr, by two-tailed Student’s t-tests. For each condition, freshly protein lysates were pooled. All reactions were performed in triplicate in the same gel
(A). H&E staining and intrahepatic TAG content assessment in anti-Mboat7-MPO or scramble-MPO mice (B). Original magniﬁcation: 400X. Hepatic Srebp1 and Fasn (genes involved
in de novo lipogenesis) (C), Ppar-a and Cpt1 (genes involved in b-oxidation) (D), Fatp1 and Fabp1 (fatty acids transporters) (E), Tnf-a and Cxcl10 (inﬂammatory markers) (F) expression was evaluated by qRT-PCR; mRNA levels were normalized to b-actin. Data are expressed as fold increase compared to Scr mice (n = 6 mice per group; *p<0.05, **p<0.01 by
two-tailed Student’s t-tests.

Wt (1.5-fold and 2.3-fold, respectively), especially for TAG with
lower saturation (i.e. 54:2/54:1/50:2/50:1) (Fig. S12). This pattern is
consistent with the heightened expression of lipogenic genes, and
with reduced MBOAT7 enzymatic activity, due to the shunting of

saturated-PI to the synthesis of DAG and TAG. A working model
depicting the potential mechanism linking decreased MBOAT7 activity to altered intracellular lipid metabolism in hepatocytes is presented in Fig. 6B.
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Fig. 5. MBOAT7 deletion increases spontaneous fat accumulation in HepG2 hepatoma cells.
Spontaneous fat accumulation in untreated MBOAT7 / cells carrying D31, D101 and D917 was evaluated by ORO staining (200X magniﬁcation) and quantiﬁed by ImageJ software in 10 random non-overlapping micrographs for each experimental condition, by calculating the percentage of pixels above the threshold value with respect to the total pixels
per area. At least three independent experiments were conducted (A). Impact of MBOAT7 deletions on hepatic fat, and MBOAT7, SREBP1c, FASn mRNA, evaluated by qRT-PCR then
normalized for b-actin (Arbitrary Units - AU). Boxes span from 25° to 75° percentile, while whiskers indicate the 10° and 90° percentile (B). * adjusted p<0.05, ** adjusted p<0.01
compared to wild-type (Wt) cells.
The D917 MBOAT7 deletion abrogates MBOAT7 expression, resulting in increased spontaneous fat accumulation, which was maintained after supplementation with palmitic
and oleic acid (PA+OA 125 mM; ratio 1:2). mRNA levels were evaluated by qRT-PCR and protein levels by Western blot and then normalized for b-actin. For each condition, freshly
protein lysates were pooled. All reactions were performed in duplicate in the same gel. **p<0.01 by two-tailed Student’s t-tests (C). Lipid accumulation was evaluated by ORO staining (200X magniﬁcation) and quantiﬁed by ImageJ software in 10 random non-overlapping micrographs for each experimental condition, by calculating the percentage of pixels
above the threshold value with respect to the total pixels per area. At least three independent experiments were conducted. * adjusted p<0.05, ** adjusted p<0.01 (D-E).

10

M. Meroni et al. / EBioMedicine 52 (2020) 102658

Fig. 6. Impact of MBOAT7 deletion on intracellular fat composition.
A) Heatmaps, which were generated calculating log2 fold change ratio between MBOAT7 / /wt absolute quantiﬁcation. Red shading indicates the induction and blue shading
indicates repression relative to the average levels of each lipid species across all samples. PI: phosphatidyl-inositol, PC: phosphatidyl-choline, PE: phosphatidyl-ethanolamine, DAG:
diacylglycerol and TAG: triacylglycerols.
B) Hypothetical model of the impact of reduced MBOAT7 activity on intracellular phospholipid metabolism in hepatocytes. The consequences of MBOAT7 downregulation are shown
by the red cross and arrows. When MBOAT7 is not functional, LysoPI (20:4) cannot be generated from LysoPI (16:0) or LysoPI (18:0), which therefore accumulate, together with their
precursors PI (36:4) and PI (38:4). Accumulating saturated-PIs are then shunted to the synthesis of TAGs.
CDP: cytidine-diphosphate, CL: cardiolipin, DAG: diacylglycerol, TAG: triacylglycerols, G3P: glyceraldehyde-3-phosphate, LPA: lyso-phosphatidic acid, PA: phosphatidic acid, PC:
phosphatidyl-choline, PE: phosphatidyl-ethanolamine, PG: phosphatidyl-glycerol, PI: phosphatidyl-inositol, PIP: phosphatidyl-inositol-phosphate, PS: phosphatidyl-serine (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.).
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Fig. 7. Fat accumulation in MBOAT7 / hepatocytes requires FATP1.
FATP1 protein levels were evaluated in lysates from wild-type (Wt), MBOAT7 / and MBOAT7 / /FATP1+/- cells by Western blot and then normalized for b-actin. For each condition, freshly protein lysates were pooled. All reactions were performed in duplicate in the same gel (A). * adjusted p<0.05 compared to Wt or MBOAT7 / cells. In Wt, MBOAT7 /
and MBOAT7 / /FATP1+/- cells SREBP1 (B), FASn (C) and ACC (D) gene expressions were evaluated by qRT-PCR and normalized for b-actin. * adjusted p<0.05; compared to Wt or
MBOAT7 / cells. Hypothetical mechanism(s) linking down-regulation of MBOAT7 in hepatocytes with hepatic fat accumulation (E). During fasting, MBOAT7 localizes to the endoplasmic reticulum and lipid droplets, where it conjugates arachidonoyl-CoA to the second acyl-chain of Lyso-PI allowing the incorporation into cell membranes. During hyperinsulinemia and in carriers of the rs641738 risk variant, MBOAT7 is reduced, increasing the concentration of saturated PI, which accumulate and are diverted to TAG synthesis. This
process requires up-regulation of the fatty acid transporter FATP1, and in vitro is associated with increased de novo lipogenesis.
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3.9. Role of FATP1 in hepatocellular fat accumulation associated with
MBOAT7 down-regulation
Consistent with the results obtained following acute Mboat7
down-regulation in mice, FATP1 protein expression was up-regulated
in MBOAT7 / compared to wild-type cells (adjusted p <0.05;
Fig. 7A). Therefore, we managed to achieve restoration of basal levels
of FATP1 expression by hemizygous FATP1 deletion in MBOAT7 /
/FATP1+/ cells (adjusted p<0.05 vs Mboat7 /- cells; Fig. S2 and
Fig. 7A). Remarkably, FATP1 down-regulation rescued the spontaneous increase in intracellular fat and reverted the induction of lipogenesis, despite persistent activation of the mTOR pathway (adjusted
p<0.05 vs MBOAT7 / ; Figs. 5D,E, 7B D, supplementary results and
Fig. S11). In MBOAT7 / /FATP1+/ cells, reduction of intracellular fat
was maintained also in the presence of fatty acids that partially suppressed lipogenesis (adjusted p <0.05 vs. untreated MBOAT7 / ; Figs.
5D,E, 7B D and Fig. S13A C). These data suggest that FATP1 up-regulation is required to allow fat deposition related to MBOAT7 downregulation.
To validate these ﬁndings in patients, we evaluated the independent determinants of hepatic FATP1 mRNA expression in the Bariatric
surgery cohort (Table S7). FATP1 was independently associated with
the presence of T2D (adjusted p = 0.01), induction of lipogenesis
(SREBP1c; adjusted p = 0.001), and inﬂammation (TNF-a; adjusted
p<0.0001). Viceversa, it was inversely associated with Mboat7
expression (adjusted p = 0.03).
4. Discussion
In this study, we examined the relationship between down-regulation of hepatic MBOAT7 and fat accumulation. We were prompted
by previous evidence that genetically determined reduction in
MBOAT7 expression is associated with increased hepatic fat [11] and
liver disease development [13 15]. Here we show that in obese individuals hepatic MBOAT7 is down-regulated with the severity of liver
damage and insulin resistance, independently of the genetic background. Furthermore, the MBOAT7 rs641738 T risk allele was associated with reduced MBOAT7 expression in human hepatocytes and
inﬂammatory cells, consistently with a role in facilitating hepatic fat
accumulation and in priming inﬂammation [34].
Down-regulation of hepatic Mboat7 was conﬁrmed in experimental models of fatty liver. The reduction was more marked during
obesity and hyperinsulinemia. Furthermore, during hyper-insulinemia in InsR+/- mice down-regulation of hepatic Mboat7 mRNA preceded the development of histological steatosis. We went on to
show that hepatic Mboat7 mRNA and protein levels are physiologically down-regulated during fasting-feeding cycles and by hyperinsulinemia in vivo and in vitro, depending on the activation of insulin
signalling [35].
We next sought independent conﬁrmation that Mboat7 downregulation is causally involved in the pathogenesis of hepatic fat
accumulation. Acute silencing of hepatic Mboat7 to levels similar to
those observed in carriers of the rs641738 risk variant increased
hepatic fat leading to the development of steatosis. The onset of
steatosis was linked to an alteration of hepatic lipid composition,
and to the up-regulation of Fatp1 and Fabp1, fatty acid transporters
in hepatocytes. Moreover, MBOAT7 deletion in HepG2 hepatoma
cells caused a spontaneous increase in intracellular fat, coupled with
an alteration of PI composition consistent with reduced total
MBOAT7 enzymatic activity. MBOAT7 is involved in the re-acylation
of phospholipids, transferring polyunsaturated acyl-CoAs, in particular arachidonoyl-CoA, to lyso-PI and other lyso-phospholipids. The
prevalent accumulation of saturated and mono-unsaturated TAG is
consistent with the increased expression of lipogenic genes, and
with the reduced MBOAT7 enzymatic activity, due to the shunting
of saturated-PI that cannot be inserted into the intracellular

membranes, to the synthesis of DAG and TAG (Fig. 6B). In addition,
the predicted accumulation of phosphatidyl-inositol-3-phosphate
due to the alteration of lyso-PI ﬂuxes may favour the tonic activation of insulin-PI3K-mTOR dependant activation of SREBP1c, contributing to the concurrent stimulation of lipogenesis that we
observed in vitro. Strengthening the robustness of these ﬁndings,
while this manuscript was under revision, Helsley et al. independently conﬁrmed that MBOAT7 is suppressed during insulin resistance, and that Mboat7 silencing promotes the development of fatty
liver mediated by the accumulation of saturated lyso-PI [36].
An intriguing ﬁnding was that MBOAT7 deletion induced FATP1
up-regulation in hepatocytes, while FATP1 hemizygous deletion in
the MBOAT7 / genetic background ameliorated the spontaneous
intracellular fat accumulation and increased lipogenesis. FATP1 is
expressed in insulin-sensitive tissues and translocates from intracellular compartments to the plasma membrane in response to insulin,
where it favours the uptake of long-chain fatty acids [37]. In addition,
FATP1 is implicated in mTOR-dependant stimulation of intracellular
fat accumulation [38]. Deletion of Fatp1 in mice impaired the regulation and redistribution of circulating FFAs following refeeding, protecting against diet-induced obesity and insulin resistance [37,39].
We also observed that in obese individuals down-regulation of
hepatic MBOAT7 was associated with increased FATP1 mRNA. Therefore, although we cannot rule out that FATP1 is a marker of hepatocellular fat accumulation independently of MBOAT7 expression,
FATP1 induction seems required to allow fat accumulation during
MBOAT7 down-regulation.
In conclusion, hyper-insulinemia, a typical feature of metabolic
syndrome and post-prandial state, reduces hepatic MBOAT7 expression via activation of the insulin signalling through the insulin receptor-PI3K pathway. Reduced MBOAT7 in turn favours hepatic fat
accumulation. These data suggest that MBOAT7 down-regulation is
implicated in mediating the effect of chronic hyperinsulinemia on
liver disease development. A working model for the mechanisms
through which MBOAT7 down-regulation induces hepatic fat accumulation is presented in Fig. 7E.
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